Table 1 Patient baseline demographics and disease characteristics
HLX01-NHL03 study | 5-year follow-up study | |||||
|---|---|---|---|---|---|---|
Characteristic | H-CHOP (N = 199) | R-CHOP (N = 203) | Total (N = 402) | H-CHOP (N = 157) | R-CHOP (N = 159) | Total (N = 316) |
Median age (range), year | 54 (46–61) | 55 (46–63) | NR | 56.9 (23.9–76.2) | 55.5 (24.4–76.6) | 56.1 (23.9–76.6) |
Sex | ||||||
Male | 118 (59.3) | 102 (50.2) | 220 (54.7) | 93 (59.2) | 79 (49.7) | 172 (54.4) |
Female | 81 (40.7) | 101 (49.8) | 182 (45.3) | 64 (40.8) | 80 (50.3) | 144 (45.6) |
ECOG PS | ||||||
0 | 75 (37.7) | 75 (36.9) | 150 (37.3) | 63 (40.1) | 65 (40.9) | 128 (40.5) |
1 | 94 (47.2) | 96 (47.3) | 190 (47.3) | 70 (44.6) | 70 (44.0) | 140 (44.3) |
2 | 30 (15.1) | 32 (15.8) | 62 (15.4) | 24 (15.3) | 24 (15.1) | 48 (15.2) |
IPI | ||||||
0 | 8 (4.0) | 7 (3.4) | 15 (3.7) | 5 (3.2) | 5 (3.1) | 10 (3.2) |
1 | 95 (47.7) | 106 (52.2) | 201 (50.0) | 70 (44.6) | 83 (52.2) | 153 (48.4) |
2 | 96 (48.2) | 90 (44.3) | 186 (46.3) | 82 (52.2) | 70 (44.0) | 152 (48.1) |
3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.6) | 1 (0.3) |
Clinical stage | ||||||
I | 20 (10.1) | 28 (13.8) | 48 (11.9) | 16 (10.2) | 27 (17.0) | 43 (13.6) |
II | 82 (41.2) | 84 (41.4) | 166 (41.3) | 63 (40.1) | 61 (38.4) | 124 (39.2) |
III | 62 (31.2) | 62 (30.5) | 124 (30.8) | 48 (30.6) | 52 (32.7) | 100 (31.6) |
IV | 35 (17.6) | 29 (14.3) | 64 (15.9) | 30 (19.1) | 19 (11.9) | 49 (15.5) |
Bone marrow involvement | ||||||
Yes | 34 (17.1) | 32 (15.8) | 66 (16.4) | 30 (19.1) | 26 (16.4) | 56 (17.7) |
No | 165 (82.9) | 171 (84.2) | 336 (83.6) | 127 (80.9) | 133 (83.6) | 260 (82.3) |